



Vita Life Sciences Limited
Appendix 4D
For the half year ended 30 June 2014

To : Company Announcements

Company: Australian Securities Exchange Fax No.:

Date: 18 August 2014 No. of pages 26 incl. cover

From: Matthew Beckett Fax No.:

Subject : **Appendix 4D**

Please see attached 30 June 2014 Half Yearly Report for Vita Life Sciences Limited (ASX - VSC).

This announcement is made pursuant to Listing rule 4.2A.3. For all enquiries please contact

Mr Matthew Beckett
Company Secretary
Vita Life Sciences Limited

Telephone 03 9828 0500

Fax 03 9820 5957

1. Company details

Name of entity

VITA LIFE SCIENCES LIMITED

ABN or equivalent company reference	Half year ended ('current period')	Half year ended (‘previous period’)
35 003 190 421	30 June 2014	30 June 2013

The information contained in this report is to be read in conjunction with Vita Life Sciences Limited’s 2013 Annual Report and any announcements to the market by Vita Life Sciences Limited during the half year ended 30 June 2014.

2. Results for announcement to the market

		Percentage Change %	2014 A\$'000
2.1	Revenue	up 3.8	17,739
	Profit before income tax	up 31.5	3,337
2.2	Net profit after tax	up 117.1	4,658
2.3	Net profit attributable to members	up 118.2	4,661

2.4	Dividends (distributions)		Amount per security	Franked amount per security
2.5	Interim 2014 dividend	Ex-Dividend Record Date To Be Paid	1.5 cents	0.0 cents
		16 September 2014 18 September 2014 25 September 2014		
	Final 2013 dividend	Record Date Paid	2.0 cents	0.0 cents
		21 March 2014 28 March 2014		

2.6 Brief explanation of any of the figures in 2.1 to 2.4 above necessary to enable the figures to be understood.

The Board of Directors is pleased to announce Vita Life Sciences Limited's ("Group") revenue for the 6 months to June 2014 was \$17.739m (2013: \$17.083m) with EBIT of \$3.337m, up 30.4% on HY2013 of \$2.542m. The inclusion of a \$2.112m income tax credit resulting from the recognition of Australian tax losses carried forward as a deferred tax asset positively impacted a net profit after tax of \$4.658m.

Revenue growth against that for the 6 months to 30 June 2013 was 3.8%. The focus on the sale of higher margin product had a positive impact, with gross margins increasing across all 3 'established' countries when measured against the six months to June 2013.

The Group's Other Asian businesses (China, Malaysia MLM, Thailand, Vietnam and Indonesia) continued to show promising signs with revenue increasing by 16.3%, despite a decline in revenue in Thailand due to the prevailing political situation.

EBIT margins across the Group as a whole are being aided by the attainment of critical mass in individual markets and the leveraging of the fixed cost base.

The Group's divisional result for 1st Half 2014 is summarised in the table below:

Half year ended 30 June	2014			2013		
	Health \$'000	Investment \$'000	Total \$'000	Health \$'000	Investment \$'000	Total \$'000
Revenue						
Sales to external customers	17,739	-	17,739	17,083	-	17,083
Total segment revenue	17,739	-	17,739	17,083	-	17,083
Result						
Segment results	3,599	(16)	3,582	2,763	(10)	2,753
Unallocated expenses			(189)			(163)
Profit before tax and finance costs			3,393			2,590
Finance costs			(56)			(52)
Profit before income tax			3,337			2,538
Income tax expense			1,321			(392)
Net profit for the year			4,658			2,146

3. Net tangible assets

	30 June 2014	30 June 2013
Net Tangible Assets per security	\$0.30	\$0.26

4. Entities over which control has been gained or lost during the period

Gain of control over entities Nil

Loss of control over entities Nil

5. Dividends

An unfranked dividend of 2.0 cents per share amounting to \$1,125,000 was paid on 28 March 2014 in relation to the year ended 31 December 2013.

Directors have declared the payment of an unfranked interim dividend for the six months to June 2014 of 1.5 cents per ordinary share as disclosed at point 2.4 above. This dividend contains no Foreign Conduit Income.

6. Dividend Reinvestment plans

The Board of Directors have resolved to suspend the Company's DRP until further notice.

7. Details of associates and joint venture entities

Investment details	Place of Incorporation	Ownership Interest	
		30 June 2014	30 June 2013
		%	%
Name of Company			
<i>Unlisted</i>			
- Mitre Focus Sdn Bhd	Malaysia	6.3	6.3

8. For foreign entities, which accounting standards were used in compiling this report.

International Financial Reporting Standard - IFRS

9. Information on Audit or Review

This interim report is based on accounts to which one of the following applies

- The accounts have been subject to review
- The accounts are in the process of being subject to review
- The accounts have not yet been reviewed

Description of likely dispute or qualification if the accounts have not yet been audited or subject to review or are in the process of being audited or subjected to review.

Not applicable



Half Year Report 30 June 2014



Contents

Directors' Report	1
Auditor's Independence Declaration	3
Condensed Consolidated Statement of Comprehensive Income	4
Condensed Consolidated Statement of Financial Position	5
Condensed Consolidated Statement of Cash Flow	6
Condensed Consolidated Statement of Changes in Equity	7
Notes to the Condensed Consolidated Financial Statements	9
Directors' Declaration	16
Independent Review Report	17
General Information	19



Directors' Report

The Directors of Vita Life Sciences Limited ("Company" or "Vita Life") submit their report together with the financial report for Vita Life and its controlled entities for the half year ended 30 June 2014.

DIRECTORS

The names of the Company's directors in office throughout and since the end of the last financial period are set out below.

Mr Vanda R Gould	Non-executive chairman
Mr Eddie L S Tie	Managing director
Mr Henry G Townsing	Non-executive director
Mr Jonathan J Tooth	Non-executive director

All directors have been in office since the start of the financial year to the date of this report unless otherwise stated.

PRINCIPAL ACTIVITIES

During the period in review the principal continuing activities of the consolidated entity consisted of formulating, packaging, sales and distribution of vitamins and supplements and investment.

OPERATING AND FINANCIAL REVIEW

Operating Results for the Half Year

For the reporting period the consolidated entity recorded a consolidated profit after tax attributable to members of the parent of the Group of \$4,661,000 (2013: \$2,136,000).

This includes income resulting from the recognition of a deferred tax asset arising from tax losses carried forward in the Australian Consolidated Tax Group of \$2,112,000.

ROUNDING OFF

The Company is of a kind referred to in ASIC Class Order 98/100 dated 10 July 1998 and in accordance with that Class Order, amounts in the financial report and Directors' report have been rounded off to the nearest thousand dollars, unless otherwise stated.

Directors' Report (continued)

AUDITOR'S INDEPENDENCE DECLARATION

The Directors have received an Independence Declaration from the external auditor, Russell Bedford NSW. A copy of this Declaration follows the Directors Report.

Signed in accordance with a resolution of the Board of Directors made pursuant to s.306(3) of the Corporations Act 2001.

A handwritten signature in black ink, appearing to be 'Eddie L S Tie', with a long horizontal line extending to the right.

Eddie L S Tie
Managing Director
Kuala Lumpur, 15 August 2014

Auditor's Independence Declaration



Russell Bedford

New South Wales

Level 42, Suncorp Place
259 George Street
Sydney NSW 2000
Australia

T: **+61 2 9032 3050**

F: +61 2 9032 3058

E: mail@russellbedfordnsw.com.au

W: www.russellbedford.com.au

15 August 2014

The Board of Directors
Vita Life Sciences Limited
Suite 650, Level 6
1 Queens Road. St Kilda Towers
MELBOURNE VIC 3004

LEAD AUDITOR'S INDEPENDENCE DECLARATION UNDER SECTION 307C OF THE CORPORATIONS ACT 2001

As lead auditor for the review of the financial statements of Vita Life Sciences Limited for the half year ended 30 June, 2014, I declare that, to the best of my knowledge and belief, there has been no contravention of:

- the auditor independence requirements as set out in the Corporations Act 2001 in relation to the review; and
- contraventions of any applicable code of professional conduct in relation to the review.

RUSSELL BEDFORD NSW
Chartered Accountants

A handwritten signature in blue ink, appearing to read 'Stephen Fisher'.

Stephen Fisher
Partner



Member of Russell Bedford International – with affiliated offices worldwide

Liability limited by a scheme approved under Professional Standards Legislation

Condensed Consolidated Statement of Comprehensive Income

For the half year ended 30 June 2014

	Notes	2014 \$'000	2013 \$'000
CONTINUING OPERATIONS			
Sale of goods		17,739	17,083
Cost of sales		(5,044)	(5,621)
Gross profit		12,695	11,462
Other income		8	44
Distribution expenses		(1,527)	(1,461)
Marketing expenses		(1,136)	(1,014)
Occupancy expenses		(412)	(380)
Administrative expenses		(6,132)	(5,911)
Other expenses		(170)	(191)
Share of associates (loss) / profit		(11)	(7)
Profit from continuing operations before interest and taxes		3,315	2,542
Finance income		78	48
Finance costs		(56)	(52)
Profit before income tax		3,337	2,538
Income tax benefit / (expense)		1,321	(392)
Net profit for the period		4,658	2,146
Other comprehensive income after income tax			
Exchange differences on translating foreign controlled entities		(507)	762
Other comprehensive (expense) / income for the period, net of income tax		(507)	762
Total comprehensive income for the period		4,151	2,908
(Loss) / profit attributable to minority interest		(3)	10
Profit attributable to members of the parent		4,661	2,136
		4,658	2,146
Total comprehensive income / (expense) attributable to:			
Minority interest		(6)	17
Members of the parent		4,157	2,891
		4,151	2,908
Earnings per share (cents per share)			
- basic earnings per share	5	8.30	3.88
- diluted earnings per share	5	8.20	3.79

The Condensed Consolidated Statement of Comprehensive Income should be read in conjunction with the accompanying notes to the Half Year Report.

Condensed Consolidated Statement of Financial Position

As at 30 June 2014

	Notes	30 June 2014 \$'000	31 December 2013 \$'000
ASSETS			
Current Assets			
Cash and cash equivalents		9,686	8,973
Trade and other receivables		4,909	4,866
Inventories		5,470	6,110
Other assets		1,094	542
Total Current Assets		21,159	20,491
Non Current Assets			
Investment in associates		978	1,022
Property, plant and equipment		232	286
Intangible assets		79	83
Deferred tax assets		1,898	127
Total Non Current Assets		3,187	1,518
Total Assets		24,346	22,009
LIABILITIES			
Current Liabilities			
Trade and other payables		4,039	4,405
Current tax liability		630	533
Provisions		531	746
Total Current Liabilities		5,200	5,684
Non Current Liabilities			
Deferred Tax Liability		8	9
Provisions		58	47
Total Non Current Liabilities		66	56
Total Liabilities		5,266	5,740
Net Assets		19,080	16,269
EQUITY			
Issued capital	6	45,765	46,100
Accumulated losses		(26,087)	(29,623)
Employee share based payments reserve		592	472
Foreign currency translation reserve		(1,274)	(770)
Parent entity interest		18,996	16,179
Minority interest		84	90
Total Equity		19,080	16,269

The Condensed Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes to the Half Year Report.

Condensed Consolidated Statement of Cash Flow

For the half year ended 30 June 2014

	Notes	2014 \$'000	2013 \$'000
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipt from customers		19,210	18,723
Payments to suppliers and employees		(15,806)	(16,012)
Borrowing costs		(56)	(52)
Income tax paid		(448)	(169)
Interest received		78	48
Net cash flows provided by operating activities		2,978	2,538
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment		(617)	(183)
Net cash flows (used in)/provided by investing activities		(617)	(183)
CASH FLOWS FROM FINANCING ACTIVITIES			
Dividends Paid		(1,125)	(274)
Proceeds from loan repayment from LTIP		-	407
Shares bought back (net of costs)		(335)	(106)
Net cash flows provided by financing activities		(1,460)	27
Net increase in cash and cash equivalents		901	2,382
Net foreign exchange differences		(188)	200
Cash and cash equivalents at beginning of the period		8,973	5,017
Cash and cash equivalents at end of the period		9,686	7,599

The Condensed Consolidated Statement of Cash Flow should be read in conjunction with the accompanying notes to the Half Year Report.

Condensed Consolidated Statement of Changes in Equity

for the half year ended 30 June 2014



	Note	Issued Capital \$'000	Employee Share Based Payments Reserve \$'000	Accumulated Losses \$'000	Foreign Currency Translation Reserve \$'000	Attributable to Equity Holders of Parent \$'000	Minority Interests \$'000	Total \$'000
Balance at 1 January 2014		46,100	472	(29,623)	(770)	16,179	90	16,269
Comprehensive income								
Profit for the period		-	-	4,661	-	4,661	(3)	4,658
Other comprehensive income for the year		-	-	-	(504)	(504)	(3)	(507)
Total comprehensive income for the period		-	-	4,661	(504)	4,157	(6)	4,151
Transactions with owners, in their capacity as owners								
Shares bought back		(335)	-	-	-	(335)	-	(335)
Employee share option scheme		-	120	-	-	120	-	120
Dividends paid	7	-	-	(1,125)	-	(1,125)	-	(1,125)
Total transactions with owners		(335)	120	(1,125)	-	(1,340)	-	(1,340)
Balance at 30 June 2014		45,765	592	(26,087)	(1,274)	18,996	84	19,080

The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes to the Half Year Report.



Condensed Consolidated Statement of Changes in Equity

for the half year ended 30 June 2014 (Cont.)

	Note	Issued Capital \$'000	Employee Share Based Payments Reserve \$'000	Accumulated Losses \$'000	Foreign Currency Translation Reserve \$'000	Attributable to Equity Holders of Parent \$'000	Minority Interests \$'000	Total \$'000
Balance at 1 January 2013		45,956	472	(33,532)	(1,640)	11,256	86	11,342
Comprehensive income								
Profit for the period		-	-	2,136	-	2,136	10	2,146
Other comprehensive income for the year		-	-	-	755	755	7	762
Total comprehensive income for the period		-	-	2,136	755	2,891	17	2,908
Transactions with owners, in their capacity as owners								
Shares bought back		(106)	-	-	-	(106)	-	(106)
Repayment of loans on Employee share option scheme		407	-	-	-	407	-	407
Dividends paid	7	-	-	(274)	-	(274)	-	(274)
Total transactions with owners		301	-	(274)	-	27	-	27
Balance at 30 June 2013		46,257	472	(31,670)	(885)	14,174	103	14,277

The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes to the Half Year Report.

Notes to the Condensed Consolidated Financial Statements

for the half year ended 30 June 2014

1. CORPORATE INFORMATION

The Half Year financial report of Vita Life Sciences Limited ("Vita Life") and its controlled entities ("the Group") for the half year ended 30 June 2014 was authorised for issue by a resolution of the directors on the date of this report.

Vita Life is a Company limited by shares incorporated and domiciled in Australia whose shares are publicly traded on the Australian Securities Exchange ("ASX").

The nature of the operations and principal activities of the Group are described in the Director's Report.

2. BASIS OF PREPARATION

These general-purpose condensed consolidated financial statements for the half-year reporting period ended 30 June 2014, have been prepared in accordance with the requirements of the *Corporations Act 2001*, and Australian Accounting Standard AASB 134 "Interim Financial Reporting." The Group is a for-profit entity for financial reporting purposes under Australian Accounting Standards.

This interim financial report is intended to provide users with an update on the latest annual financial statements of Vita Life Sciences Limited. As such, it does not contain information that represents relatively insignificant changes occurring during the half-year within the Group. It is therefore recommended that this financial report be read in conjunction with the annual financial statements of the Group for the year ended 31 December 2013, together with any public announcements made during the following half-year.

The same accounting policies and methods of computation have been followed in this interim financial report as were applied in the most recent annual financial statements.

The half-yearly condensed consolidated financial statements have been prepared on a historical cost basis.

For the half-year reporting period to 30 June 2014, a number of new and revised Accounting Standard requirements became mandatory for the first time, however none of these were applicable to the Group's financial reporting policies.

Notes to the Condensed Consolidated Financial Statements

for the half year ended 30 June 2014 (continued)

2. SEGMENT REPORTING

	Australia \$'000	Singapore \$'000	Malaysia \$'000	Others \$'000	Total \$'000
Half year ended 30 June 2014					
Revenue					
Sales to external customers	6,571	2,580	6,815	1,773	17,739
Segment results					
Profit / (loss) before tax and finance costs	1,019	1,175	1,342	(132)	3,404
Finance costs	(23)	(1)	(28)	(4)	(56)
Share of loss of associates				(11)	(11)
Profit before income tax					3,337
Income tax expense					1,321
Net profit for the period					4,658
Assets and liabilities					
Segment assets	9,134	2,931	8,405	2,898	23,368
Investment in associates					978
Total assets					24,346
Segment liabilities	2,097	650	2,223	296	5,266
Total liabilities					5,266
Other segment information					
Capital expenditure	-	(12)	(601)	(4)	(617)
Depreciation	(5)	(1)	(25)	(12)	(43)
Amortisation	-	(6)	(1)	-	(7)

Notes to the Condensed Consolidated Financial Statements

for the half year ended 30 June 2014 (continued)

3. SEGMENT REPORTING (CONTINUED)

	Australia \$'000	Singapore \$'000	Malaysia \$'000	Others \$'000	Total \$'000
Half year ended 30 June 2013					
Revenue					
Sales to external customers	6,925	2,741	5,945	1,472	17,083
Segment results					
Profit / (loss) before tax and finance costs	804	967	997	(171)	2,597
Finance costs	(24)	(1)	(25)	(2)	(52)
Share of profit of associates				(7)	(7)
Profit before income tax					2,538
Income tax expense					(392)
Net profit for the period					2,146
Assets and liabilities					
Segment assets	7,745	2,770	6,590	2,444	19,549
Investment in associates					1,044
Total assets					20,593
Segment liabilities	2,626	851	2,680	159	6,316
Total liabilities					6,316
Other segment information					
Capital expenditure	(7)	(61)	(89)	(26)	(183)
Depreciation	(3)	(17)	(13)	(4)	(37)
Amortisation	-	(5)	(1)	(1)	(7)

Notes to the Condensed Consolidated Financial Statements

for the half year ended 30 June 2014 (continued)

4. NET TANGIBLE ASSETS

	30 June 2014 \$	31 Dec 2013 \$
Net assets per share	0.34	0.29
Net tangible assets per share	0.30	0.29
	Number	Number
Weighted average number of ordinary shares for net assets per share	56,167,913	56,250,650

5. EARNINGS PER SHARE

	30 June 2014 \$'000	30 June 2013 \$'000
(a) Earnings used in calculating earnings per share		
Net profit attributable to equity holders from continuing operations	4,658	2,146
(Profit) / Loss attributable to minority interest	3	(10)
Net profit attributable to equity holders of the parent used to calculate EPS	4,661	2,136
	Number	Number
(b) Weighted average number of shares		
Weighted average number of ordinary shares for basic earnings per share	56,167,913	55,013,690
Adjusted weighted average number of ordinary shares for diluted earnings per share	56,812,913	56,426,190

Notes to the Condensed Consolidated Financial Statements

for the half year ended 30 June 2014 (continued)

6. ISSUED CAPITAL

	30 June 2014	30 June 2013	30 June 2014	30 June 2013
	Number	Number	\$	\$
Issued and paid up capital				
Ordinary shares	56,688,222	56,369,295	45,765,443	4,625,952
Ordinary shares				
Balance at beginning of the financial period	56,250,650	56,474,638	46,100,480	45,956,146
Share buy back (a)	(207,428)	(105,343)	(335,037)	(105,994)
Issue of shares to employees (b)	645,000	-	-	-
Plan shares exercised	-	-	-	406,800
Balance at end of the financial period	56,688,222	56,369,295	45,765,443	46,256,952

- a) A total of 207,428 ordinary shares were bought back in the half year ended 30 June 2014 as approved by the shareholders in the 23 May 2013 and 22 May 2014 Annual General Meetings at a total cost of \$335,037.
- b) During the half year ended 30 June 2014, the Company approved loans to three senior executives of the Group totaling \$741,750 in order for these executives to purchase a total of 645,000 shares under the Company's Long Term Incentive Plan.

The issue of these shares was ratified at the Company's Annual General Meeting held on 22 May 2014.

The cost of the equity-settled transactions is measured by reference to the fair value of the equity instruments at the date at which they were granted. The cost is recognised in the income statement together with a corresponding increase in equity, over the period in which the performance and / or service conditions are fulfilled (the vesting period), ending on the date on which the employees become fully entitled to the award (the vesting date).

For the half year ended 30 June 2014, the Company recognised \$120,144 (1st Half 2013: \$Nil) in the income statement with a corresponding increase in employee share based payment reserve.

7. DIVIDEND

An unfranked dividend of 2.0 cents per share amounting to \$1,125,000 (2013: 0.5 cents per share fully franked totalling \$274,000) was paid on 28 March 2014 in relation to the year ended 31 December 2013.

An unfranked interim dividend of 1.5 cents per share has been declared and will be paid on 25 September 2014. The record date for the interim dividend is 18 September 2014.

Notes to the Condensed Consolidated Financial Statements

for the half year ended 30 June 2014 (continued)

8. COMMITMENTS

A contract of sale has been signed for RM18,500,000 for the new premises in Kuala Lumpur, of which a deposit of RM1,850,000 has been paid. Conditional upon the vendor's shareholders approving the contract of sale at a General Meeting, the Group has a commitment to pay the remaining RM16,650,000 (approximately \$5,504,000) at settlement, which is expected to occur sometime in September 2014.

There are no other significant changes to the commitments as previously disclosed in the Annual Report for the financial year ended 31 December 2013.

9. EVENTS AFTER THE BALANCE SHEET DATE

On 24 July 2014, the Group received confirmation from the Inland Revenue Authority of Singapore that tax losses totalling SD\$18,992,000 (approximately \$16,143,000) relating to one of the Group's wholly owned subsidiaries are available for offset against future taxable income.

Other than those mentioned in the financial statements and notes thereto, no matters or circumstances have arisen since the end of the financial period which significantly affected or could significantly affect the operations of the economic entity, the results of those operations or the state of affairs of the economic entity in future financial years.

10. CONTINGENT ASSETS AND LIABILITIES

The Group has no contingent assets or liabilities as at 30 June 2014.

Notes to the Condensed Consolidated Financial Statements

for the half year ended 30 June 2014 (continued)

11. RELATED PARTIES DISCLOSURES

Transactions with related parties

The following table provides the total amount of transactions that were entered into with related parties for the relevant financial period.

	CONSOLIDATED	
	30 June 2014	30 June 2013
	\$	\$
Other transactions with related parties		
Business Intelligence & Support Inc. (i)	243,127	292,140
CVC Venture Managers Pty Ltd (ii)	71,034	50,091
Pilmora Pty Ltd (iii)	11,500	7,500
Melbourne Corporation Pty Ltd	-	15,975
	325,661	365,706

- (i) Business Intelligence & Support Inc., a company in which Mr Eddie Tie is a director, and therefore a related party, provided international business advisory, sales, marketing and promotion services to the Group. \$236,142 remained payable as at 30 June 2014, and is disclosed in trade and other payables.
- (ii) CVC Venture Managers Pty Limited, a company in which Mr Henry Townsing is a director, was paid consultancy fees during the financial period. \$3,908 remained payable as at 30 June 2014, and is disclosed in trade and other payables.
- (iii) Pilmora Pty Ltd, a company in which Mr Henry Townsing is a director, was paid a consultancy fee during the financial period. \$11,500 remained payable as at 30 June 2014, and is disclosed in trade and other payables.

Directors' Declaration

In the opinion of the directors of Vita Life Sciences Limited:

1. (a) The financial statements and notes of the consolidated entity are in accordance with the *Corporations Act 2001*, including:
 - (i) giving a true and fair view of the consolidated entity's financial position as at 30 June 2014 and its performance for the half-year ended on that date; and
 - (ii) complying with Accounting Standard AASB 134 *Interim Financial Reporting*, Corporations Regulations 2001 and other mandatory professional reporting requirements.
- (b) There are reasonable grounds to believe that the consolidated entity will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of the directors made pursuant to s.303(5) of the Corporations Act 2001:



Eddie L S Tie
Managing Director
Kuala Lumpur, 15 August 2014

Independent Review Report



Russell Bedford

New South Wales

Level 42, Suncorp Place
259 George Street
Sydney NSW 2000
Australia

T: **+61 2 9032 3050**

F: +61 2 9032 3058

E: mail@russellbedfordnsw.com.au

W: www.russellbedford.com.au

Independent Review Report To the members of Vita Life Sciences Limited

Report on the Half-Year Financial Report

We have reviewed the accompanying half-year financial report of Vita Life Sciences Limited and the entities it controlled during the period which comprises the condensed consolidated statement of financial position as at 30 June 2014, the condensed consolidated statement of comprehensive income, condensed consolidated statement of changes in equity, condensed consolidated statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Directors Responsibility on the Half-Year Financial Report

The directors of Vita Life Sciences Limited are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards (including Australian Accounting Interpretations) and the Corporations Act 2001 and for such control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410: Review of an Interim Financial Report Performed by the Independent Auditor of the Entity, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the financial report is not in accordance with the Corporations Act 2001 including: giving a true and fair view of the company's financial position as at 30 June 2014 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001. As auditor of Vita Life Sciences Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Our review did not involve an analysis of the prudence of business decisions made by directors or management.



Member of Russell Bedford International – with affiliated offices worldwide

Liability limited by a scheme approved under Professional Standards Legislation

Matters Relating to Electronic Publication of the Reviewed Financial Report

This review report relates to the financial report of Vita Life Sciences Limited for the half year period ended 30 June 2014 included on the website of Vita Life Sciences Limited. The directors of the company are responsible for the integrity of the website and we have not been engaged to report on this integrity. This review report refers only to the subject matter described above. It does not provide an opinion on any other information which may have been hyperlinked to or from the financial report. If users of the financial report are concerned with the inherent risk arising from publication on a website, they are advised to refer to the hard copy of the reviewed financial report to confirm the information contained in this website version of the financial report.

Independence

In conducting our review, we have complied with the independence requirements of the Corporations Act 2001.

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Vita Life Sciences Limited and the entities it controlled during the period is not in accordance with the Corporations Act 2001 including:

- a) giving a true and fair view of the consolidated entity's financial position as at 30 June 2014 and of its performance for the half-year ended on that date; and
- b) complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001.

RUSSELL BEDFORD NSW
Chartered Accountants



Stephen Fisher
Partner

Sydney, 15 August 2014



General Information

Board of Directors

Vanda Gould
Chairman

Eddie L S Tie
Managing Director

Jonathan Tooth
Non-Executive Director

Henry Townsing
Non-Executive Director

Company Secretary
Matthew Beckett

Corporate Office
Suite 650, Level 6
1 Queens Road
Melbourne VIC 3004
T: 61 (03) 9828 0500
F: 61 (03) 9820 5957

Australian Regional Office
Unit 1/ 102, Bath Road
Kirrawee
NSW 2232
T: 61 (02) 9545 2633
F: 61 (02) 9545 1311

Asian Regional Office
81G, Jalan SS 21/60
Damansara Utama
47400 Petaling Jaya
Malaysia
T: 60 (03) 7729 3873
F: 60 (03) 7727 4658

Securities Exchange Listing

The ordinary shares of Vita Life Sciences Limited are listed on the Australian Securities Exchange Ltd (code: VSC).

Auditor

Russell Bedford NSW
Level 42, Suncorp Place
259 George Street
Sydney NSW 2000

Banker

Westpac Banking Corporation

National Australia Bank Limited

Solicitor

Steven Kunstler

Share Registry

Gould Ralph Pty Ltd
Level 42, Suncorp Place
259 George Street
Sydney NSW 2000
T: 61 (02) 9032 3000
F: 61 (02) 9032 3088

Change of Address

Shareholders who have changed address should advise our share registry in writing.

Annual Report Mailing

Shareholders who do not want the annual report or who are receiving more than one copy should advise the share registry in writing.

Vita Life Website

Vita Life has a website containing information about the Company, its Business and Products.

www.vitalifesciences.com.au

VLS